| scholarly article | Q13442814 |
| P50 | author | Kevin H. Gardner | Q37837105 |
| He Zhang | Q57768102 | ||
| Guiyang Hao | Q87996076 | ||
| P2093 | author name string | Xiankai Sun | |
| Eugene Frenkel | |||
| Richard K Bruick | |||
| Yang Xie | |||
| Eli M Wallace | |||
| James P Rizzi | |||
| John A Josey | |||
| Nirav Patel | |||
| Min Soo Kim | |||
| Xian-Jin Xie | |||
| Jenny Chang | |||
| Payal Kapur | |||
| Wenfang Chen | |||
| Tae Hyun Hwang | |||
| Eboni Holloman | |||
| Ivan Pedrosa | |||
| James Brugarolas | |||
| Renée M McKay | |||
| Yuanqing Ma | |||
| Tai Wong | |||
| Heather Geiger | |||
| Alana Christie | |||
| Naseem Zojwalla | |||
| Kevin Courtney | |||
| Allison Joyce | |||
| Haley Hill | |||
| Qurratulain Yousuf | |||
| Andrea Pavia-Jimenez | |||
| Catherine Reeves | |||
| Farrah Homayoun | |||
| Paul Yell | |||
| P2860 | cites work | HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity | Q24302129 |
| Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells | Q24314526 | ||
| Accurate whole human genome sequencing using reversible terminator chemistry | Q24641887 | ||
| A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development | Q24681396 | ||
| HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression | Q27025886 | ||
| Structural basis for PAS domain heterodimerization in the basic helix-loop-helix-PAS transcription factor hypoxia-inducible factor | Q27642763 | ||
| Artificial ligand binding within the HIF2 PAS-B domain of the HIF2 transcription factor | Q27653363 | ||
| Development of Inhibitors of the PAS-B Domain of the HIF-2α Transcription Factor | Q27676058 | ||
| Allosteric inhibition of hypoxia inducible factor-2 with small molecules | Q27676596 | ||
| Structural integration in hypoxia-inducible factors | Q27701731 | ||
| On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models | Q27727998 | ||
| A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma | Q27728074 | ||
| edgeR: a Bioconductor package for differential expression analysis of digital gene expression data | Q27860819 | ||
| Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 | ||
| Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo | Q28594830 | ||
| HTSeq--a Python framework to work with high-throughput sequencing data | Q29614489 | ||
| STAR: ultrafast universal RNA-seq aligner | Q29615052 | ||
| Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway | Q29617805 | ||
| Molecular genetics of clear-cell renal cell carcinoma | Q33729097 | ||
| Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. | Q33863055 | ||
| Fructose-1,6-bisphosphatase opposes renal carcinoma progression | Q34173576 | ||
| BAP1 loss defines a new class of renal cell carcinoma | Q34280223 | ||
| RSeQC: quality control of RNA-seq experiments | Q34284787 | ||
| Simultaneous isolation of high-quality DNA, RNA, miRNA and proteins from tissues for genomic applications | Q34414411 | ||
| HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. | Q34471121 | ||
| Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1alpha) and HIF-2alpha in stem cells | Q34564866 | ||
| HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses | Q34999383 | ||
| Establishing a human renal cell carcinoma tumorgraft platform for preclinical drug testing | Q35041892 | ||
| A complex task? Direct modulation of transcription factors with small molecules | Q35642431 | ||
| Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma | Q35807817 | ||
| A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma | Q36606040 | ||
| Mutations of the VHL tumour suppressor gene in renal carcinoma | Q42806703 | ||
| Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein | Q44043145 | ||
| In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. | Q44285254 | ||
| Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma | Q47283034 | ||
| MR classification of renal masses with pathologic correlation | Q53028087 | ||
| P433 | issue | 7627 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | renal cell carcinoma | Q1164529 |
| P304 | page(s) | 112-117 | |
| P577 | publication date | 2016-09-05 | |
| P1433 | published in | Nature | Q180445 |
| P1476 | title | Targeting renal cell carcinoma with a HIF-2 antagonist | |
| P478 | volume | 539 |
| Q55208909 | A 3D Human Renal Cell Carcinoma-on-a-Chip for the Study of Tumor Angiogenesis. |
| Q64067743 | A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis |
| Q64108683 | A KLF6-driven transcriptional network links lipid homeostasis and tumour growth in renal carcinoma |
| Q50201145 | A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805]). |
| Q90438681 | A Small-Molecule Pan-Id Antagonist Inhibits Pathologic Ocular Neovascularization |
| Q50120786 | A new paradigm for GERD pathogenesis. Not acid injury, but cytokine-mediated inflammation driven by HIF-2α: a potential role for targeting HIF-2α to prevent and treat reflux esophagitis. |
| Q100464168 | A system-level approach identifies HIF-2α as a critical regulator of chondrosarcoma progression |
| Q57811890 | ARNT as a Novel Antifibrotic Target in CKD |
| Q92690566 | ARNT-dependent HIF-2 transcriptional activity is not sufficient to regulate downstream target genes in neuroblastoma |
| Q98224343 | Abnormal expression and prognostic significance of EPB41L1 in kidney renal clear cell carcinoma based on data mining |
| Q47648812 | Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis. |
| Q92377648 | An immortalized cell line derived from renal erythropoietin-producing (REP) cells demonstrates their potential to transform into myofibroblasts |
| Q88676254 | Anticancer drugs: Translating the undruggable target |
| Q45141795 | Assembly and function of bHLH-PAS complexes |
| Q89761545 | Basic Biology of Hypoxic Responses Mediated by the Transcription Factor HIFs and its Implication for Medicine |
| Q92492990 | Bayesian data integration and variable selection for pan-cancer survival prediction using protein expression data |
| Q91907803 | Bidirectional modulation of HIF-2 activity through chemical ligands |
| Q54977082 | Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma. |
| Q47711163 | Cell death-based approaches in treatment of the urinary tract-associated diseases: a fight for survival in the killing fields. |
| Q92966885 | Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy |
| Q90119301 | Cellular adaptation to hypoxia through hypoxia inducible factors and beyond |
| Q58104077 | Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma |
| Q101216963 | Clear cell renal cell carcinoma ontogeny and mechanisms of lethality |
| Q93048619 | Clinical implications of the oncometabolite succinate in SDHx-mutation carriers |
| Q48725316 | Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression |
| Q44316914 | Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice |
| Q89766118 | Comprehensive transcriptomic profiling reveals SOX7 as an early regulator of angiogenesis in hypoxic human endothelial cells |
| Q52661758 | Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma |
| Q33667686 | Current status and perspectives of patient-derived xenograft models in cancer research |
| Q94662665 | Decreased expression and hypomethylation of HDAC9 lead to poor prognosis and inhibit immune cell infiltration in clear cell renal cell carcinoma |
| Q39441380 | Developing Cures: Targeting Ontogenesis in Cancer. |
| Q39089351 | Discovery of a murine model of clinical PAH: Mission impossible? |
| Q58594889 | EZH2 Expression is increased in BAP1-mutant renal clear cell carcinoma and is related to poor prognosis |
| Q47600932 | EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming |
| Q99626389 | Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma |
| Q58786758 | Endogenous HIF2A reporter systems for high-throughput functional screening |
| Q64101007 | Epigenetic regulator G9a provides glucose as a sweet key to stress resistance |
| Q41574276 | Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma |
| Q48248980 | Establishment of a bioluminescent Renca cell line for renal carcinoma research. |
| Q38676794 | Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma |
| Q59813118 | Fabrication and evaluation of a γ-PGA-based self-assembly transferrin receptor-targeting anticancer drug carrier |
| Q92445423 | Functional Interaction of Hypoxia-Inducible Factor 2-Alpha and Autophagy Mediates Drug Resistance in Colon Cancer Cells |
| Q52590924 | Generation of autochthonous mouse models of clear cell renal cell carcinoma: mouse models of renal cell carcinoma |
| Q89361082 | Genetic and metabolic hallmarks of clear cell renal cell carcinoma |
| Q89548850 | Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss |
| Q64889985 | Glutamate induces synthesis of thrombogenic peptides and extracellular vesicle release from human platelets. |
| Q99564929 | Glutamine reliance in cell metabolism |
| Q41472694 | HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1α and HIF-2α balance in renal cell carcinoma |
| Q61445354 | HER2 regulates HIF-2α and drives an increased hypoxic response in breast cancer |
| Q61818612 | HIF-1α and HIF-2α Differently Regulate the Radiation Sensitivity of NSCLC Cells |
| Q98513545 | HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice |
| Q90396000 | HIF-1α-derived cell-penetrating peptides inhibit ERK-dependent activation of HIF-1 and trigger apoptosis of cancer cells under hypoxia |
| Q47568377 | HIF-2alpha: Achilles' heel of pseudohypoxic subtype paraganglioma and other related conditions |
| Q100464172 | HIF-2α is indispensable for regulatory T cell function |
| Q90424574 | HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species |
| Q100737012 | HIF1α is not a target of 14q deletion in clear cell renal cancer |
| Q49559079 | HIF2 Inhibitor Joins the Kidney Cancer Armamentarium |
| Q58550889 | HIF2A-LOX pathway promotes fibrotic tissue remodeling in thyroid-associated orbitopathy |
| Q54858561 | Hypoxia and Inflammation in Cancer, Focus on HIF and NF-κB. |
| Q50070013 | Hypoxia and hypoxia-inducible factors in neuroblastoma |
| Q41559175 | Hypoxia inducible factor (HIF) as a model for studying inhibition of protein-protein interactions |
| Q47893488 | Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe? |
| Q38685135 | Hypoxia inducible factors in hepatocellular carcinoma |
| Q98289786 | Hypoxia promoted renal cell carcinoma cell migration through regulating lncRNA-ENST00000574654.1. |
| Q38913214 | Hypoxia, pseudohypoxia and cellular differentiation |
| Q55419613 | Hypoxia-Inducible Factor 2-Dependent Pathways Driving Von Hippel-Lindau-Deficient Renal Cancer. |
| Q39456881 | Hypoxia-Inducible Factors: Master Regulators of Cancer Progression |
| Q92959489 | Hypoxic Regulation of Neutrophils in Cancer |
| Q58104112 | Imaging Advances in the Management of Kidney Cancer |
| Q93078948 | Inherent DNA-binding specificities of the HIF-1α and HIF-2α transcription factors in chromatin |
| Q38769432 | Integration of hypoxic HIF-α signaling in blood cancers |
| Q55400356 | Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer. |
| Q53779030 | Kidney cancer in 2016: RCC - advances in targeted therapeutics and genomics |
| Q50285883 | Kidney cancer in 2016: The evolution of anti-angiogenic therapy for kidney cancer |
| Q88420250 | Kidney cancer: HIF-2α - a new target in RCC |
| Q57141762 | Kidney cancer: The next decade |
| Q52649603 | LncRNA LOC653786 promotes growth of RCC cells via upregulating FOXM1. |
| Q47161583 | Low neighbor of Brca1 gene expression predicts poor clinical outcome and resistance of sunitinib in clear cell renal cell carcinoma |
| Q91754912 | MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma |
| Q93134158 | Mechanisms of hypoxia signalling: new implications for nephrology |
| Q39340415 | Metabolic Alterations in Cancer and Their Potential as Therapeutic Targets |
| Q49832801 | Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2α Inhibitor PT2385 In Vivo and In Vitro |
| Q90073357 | Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors |
| Q39290307 | Metabolic reprogramming in clear cell renal cell carcinoma |
| Q52618376 | Metabolomics and Metabolic Reprogramming in Kidney Cancer |
| Q92471913 | Metabolomics informs common patterns of molecular dysfunction across histologies of renal cell carcinoma |
| Q57153919 | Metastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options |
| Q33844924 | Mitochondrial Deficiencies in the Predisposition to Paraganglioma |
| Q90316776 | Modulation of HIF-2α PAS-B domain contributes to physiological responses |
| Q47610334 | Modulators of 14-3-3 Protein-Protein Interactions |
| Q39110234 | Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy |
| Q47252459 | Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma |
| Q93379768 | Mutations in renal cell carcinoma |
| Q59301309 | NF-κB-Dependent Lymphoid Enhancer Co-option Promotes Renal Carcinoma Metastasis |
| Q90609011 | Next Generation Sequencing in Renal Cell Carcinoma: Towards Precision Medicine |
| Q57176491 | Notch signaling promotes a HIF2α-driven hypoxic response in multiple tumor cell types |
| Q27727998 | On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models |
| Q90860049 | Oncometabolites in renal cancer |
| Q92142710 | Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type |
| Q92472954 | Overexpression of BMP1 reflects poor prognosis in clear cell renal cell carcinoma |
| Q64107489 | Overexpression of HHLA2 in human clear cell renal cell carcinoma is significantly associated with poor survival of the patients |
| Q91940247 | Oxygen sensing and adaptability won the 2019 Nobel Prize in Physiology or medicine |
| Q92735085 | PAX8 activates metabolic genes via enhancer elements in Renal Cell Carcinoma |
| Q46485254 | PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma |
| Q89761556 | Patient-Derived Xenograft Models in Urological Malignancies: Urothelial Cell Carcinoma and Renal Cell Carcinoma |
| Q64900872 | Patient-derived xenograft models to optimize kidney cancer therapies. |
| Q38714374 | Patient-derived xenografts as in vivo models for research in urological malignancies |
| Q90963815 | Pharmacologic Targeting of Hypoxia-Inducible Factors |
| Q47283034 | Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma |
| Q47557996 | Pheochromocytomas and Hypertension. |
| Q64964635 | Pheochromocytomas and Paragangliomas: Bypassing Cellular Respiration. |
| Q92702306 | Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies |
| Q96610330 | Pivotal biomarker expression and drug screening in advanced ccRCC |
| Q55265947 | Prognostic Role of Hypoxia-Inducible Factor-2α Tumor Cell Expression in Cancer Patients: A Meta-Analysis. |
| Q91574563 | Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment |
| Q58702903 | Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression |
| Q47708732 | Regulation of immunity and inflammation by hypoxia in immunological niches |
| Q50297707 | Renal Cell Carcinoma in von Hippel-Lindau Disease-From Tumor Genetics to Novel Therapeutic Strategies |
| Q57178229 | Renal Cell Carcinoma: Molecular Aspects |
| Q30235364 | Renal cell carcinoma |
| Q52724797 | Renal cell carcinoma: a review of biology and pathophysiology. |
| Q39157961 | Renal cell carcinoma: molecular characterization and evolving treatment paradigms. |
| Q98291421 | Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs |
| Q89393258 | Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies |
| Q57296955 | Role of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and Plasticity |
| Q55638461 | SINHCAF/FAM60A and SIN3A specifically repress HIF-2α expression. |
| Q50107305 | SOD3 improves the tumor response to chemotherapy by stabilizing endothelial HIF-2α. |
| Q47402308 | SREBP-1c as a molecular bridge between lipogenesis and cell cycle progression of clear cell renal carcinoma. |
| Q59790989 | TRIM2 downregulation in clear cell renal cell carcinoma affects cell proliferation, migration, and invasion and predicts poor patients' survival |
| Q47611824 | Targeting HIF2 in Clear Cell Renal Cell Carcinoma |
| Q38674277 | Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy |
| Q48922902 | Targeting SPOP with small molecules provides a novel strategy for kidney cancer therapy |
| Q100455154 | Targeting the HIF2-VEGF axis in renal cell carcinoma |
| Q90003131 | Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression |
| Q91666595 | The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications |
| Q50026055 | The HIF and other quandaries in VHL disease |
| Q41636614 | The Roles of Hypoxia Signaling in the Pathogenesis of Cardiovascular Diseases |
| Q41112435 | The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer |
| Q39246376 | The hypoxia signalling pathway in haematological malignancies. |
| Q41709310 | The long noncoding RNA HOTAIR activates the Hippo pathway by directly binding to SAV1 in renal cell carcinoma |
| Q47642170 | The role of hypoxia-inducible factors in carotid body (patho) physiology. |
| Q57060192 | The role of hypoxia-inducible factors in metabolic diseases |
| Q42320961 | The therapeutic potential of HIF-2 antagonism in renal cell carcinoma |
| Q89167704 | Therapeutic Targeting of Vascular Remodeling and Right Heart Failure in Pulmonary Arterial Hypertension with a HIF-2α Inhibitor |
| Q89221781 | Tracing Renal Cell Carcinomas back to the Nephron |
| Q90348584 | Transcriptional control of kidney cancer |
| Q58585088 | Translating Metabolic Reprogramming into New Targets for Kidney Cancer |
| Q52685425 | Translational repression of HIF2α expression in mice with Chuvash polycythemia reverses polycythemia |
| Q54976476 | Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer. |
| Q50104130 | Tumor Hypoxia As an Enhancer of Inflammation-Mediated Metastasis: Emerging Therapeutic Strategies |
| Q88454524 | Tumour metabolism: Translating the undruggable target |
| Q93083199 | Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma |
| Q90077722 | Uptake of HDL-cholesterol contributes to lipid accumulation in clear cell renal cell carcinoma |
| Q54943750 | VHL and Hypoxia Signaling: Beyond HIF in Cancer. |
| Q90348788 | VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma |
| Q58584059 | VHL-Mediated Regulation of CHCHD4 and Mitochondrial Function |
Search more.